GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
TL;DR
GeoVax's GEO-CM04S1 vaccine outperforms mRNA vaccines in enhancing T cell responses among immunocompromised patients, offering a competitive edge in COVID-19 protection.
GEO-CM04S1, a synthetic MVA vector vaccine, targets both Spike and Nucleocapsid proteins of SARS-CoV-2, demonstrating superior cellular immune responses in Phase 2 trials.
GEO-CM04S1's success in immunocompromised individuals marks a significant step towards equitable COVID-19 protection, improving global health outcomes.
Discover how GeoVax's innovative GEO-CM04S1 vaccine is redefining COVID-19 immunity with its unique multi-antigen approach in immunocompromised patients.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc. has unveiled promising clinical data at the 2025 European Hematology Association Hybrid Congress, showcasing the superior performance of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia (CLL) patients. The vaccine, based on a synthetic Modified Vaccinia Ankara vector, elicited significantly enhanced T cell responses compared to an authorized mRNA-based COVID-19 vaccine in a Phase 2 trial. This development is crucial for immunocompromised individuals, particularly those with hematologic malignancies like CLL, who often exhibit suboptimal responses to conventional vaccines.
The study highlighted that GEO-CM04S1 not only stimulated humoral immune responses but also achieved statistically significant SARS-CoV-2 Nucleocapsid-specific IgG and T cell responses, a feat the mRNA vaccine could not match. With the mRNA vaccine failing to meet the primary immunogenicity endpoint, further trial enrollment is now limited to the GEO-CM04S1 arm. Both vaccines were well-tolerated, with no severe adverse events reported, underscoring the safety profile of GEO-CM04S1.
Dr. Kelly T. McKee, Jr., GeoVax's Chief Medical Officer, emphasized the clinical and immunologic advantages of their multi-antigen approach, which could address critical gaps in COVID-19 protection for vulnerable populations. The ongoing Phase 2 trials across various patient populations, including healthy adults, aim to further validate GEO-CM04S1's potential as a more robust and durable COVID-19 vaccine option.
Curated from NewMediaWire
